GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intersect ENT Inc (NAS:XENT) » Definitions » EV-to-Revenue

Intersect ENT (Intersect ENT) EV-to-Revenue : 10.21 (As of May. 06, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Intersect ENT EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Intersect ENT's enterprise value is $1,061.8 Mil. Intersect ENT's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 was $104.0 Mil. Therefore, Intersect ENT's EV-to-Revenue for today is 10.21.

The historical rank and industry rank for Intersect ENT's EV-to-Revenue or its related term are showing as below:

XENT' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.11   Med: 7.58   Max: 14.75
Current: 10.21

During the past 10 years, the highest EV-to-Revenue of Intersect ENT was 14.75. The lowest was 2.11. And the median was 7.58.

XENT's EV-to-Revenue is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 3.23 vs XENT: 10.21

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-06), Intersect ENT's stock price is $28.24. Intersect ENT's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $3.11. Therefore, Intersect ENT's PS Ratio for today is 9.08.


Intersect ENT EV-to-Revenue Historical Data

The historical data trend for Intersect ENT's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intersect ENT EV-to-Revenue Chart

Intersect ENT Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.92 7.06 6.62 9.28 9.37

Intersect ENT Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.25 5.75 9.16 9.37 10.13

Competitive Comparison of Intersect ENT's EV-to-Revenue

For the Medical Devices subindustry, Intersect ENT's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intersect ENT's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Intersect ENT's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Intersect ENT's EV-to-Revenue falls into.



Intersect ENT EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Intersect ENT's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1061.837/103.995
=10.21

Intersect ENT's current Enterprise Value is $1,061.8 Mil.
Intersect ENT's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $104.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intersect ENT  (NAS:XENT) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Intersect ENT's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=28.24/3.111
=9.08

Intersect ENT's share price for today is $28.24.
Intersect ENT's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.11.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intersect ENT EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Intersect ENT's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Intersect ENT (Intersect ENT) Business Description

Traded in Other Exchanges
N/A
Address
1555 Adams Drive, Menlo Park, CA, USA, 94025
Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.
Executives
Elisabeth Sandoval director C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Neil A Hattangadi director 1555 ADAMS DRIVE MENLO PARK CA 94025
Reyna M Fernandez officer: Chief Human Resource Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Patrick A Broderick officer: EVP, GC & Corporate Secretary C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Thomas A. West director, officer: President and CEO C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Richard A Meier officer: EVP & Chief Financial Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Binney Robert H Jr officer: Vice President, Sales 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Susan P Stimson officer: Vice President, Marketing 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Lisa D Earnhardt director, officer: See Remarks 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Aaron Lehman officer: General Counsel C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeryl L Hilleman officer: Chief Financial Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Christine R Kowalski officer: Chief Operations Officer C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Richard E Kaufman officer: See Remarks 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Gwen R. Carscadden officer: Chief People Officer C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025

Intersect ENT (Intersect ENT) Headlines

From GuruFocus

Intersect ENT to Report First Quarter 2021 Financial Results

By Business Wire Business Wire 04-20-2021

Intersect ENT to Participate in Upcoming Investor Conferences

By Business Wire Business Wire 02-02-2021